Influenza A BY PCR

The Influenza A BY PCR test uses polymerase chain reaction to detect influenza A viral RNA in respiratory specimens, providing a highly sensitive and specific diagnosis. Collected via nasal and/or throat swab during a home visit in Dubai, samples are sent to an accredited laboratory for definitive qualitative detection and may report a cycle threshold (Ct) value as a semi-quantitative indicator. As the diagnostic gold standard for influenza A, PCR testing guides timely antiviral treatment and helps inform infection-control decisions to protect household and community health.

• Influenza A viral RNA (qualitative detection)
• Cycle threshold (Ct) value — semi-quantitative indicator
• Influenza A subtype (if performed, e.g., H1N1)
• Internal control / sample adequacy

• Within 48–72 hours of onset of flu-like symptoms
• Fever accompanied by cough, sore throat, or body aches
• After close contact with a confirmed influenza A case
• Before initiating antivirals in high‑risk individuals (elderly, pregnant, chronic conditions)
• To differentiate influenza A from COVID‑19 and other respiratory infections

• High-sensitivity PCR detection for accurate diagnosis
• Home sample collection across Dubai with lab-accredited processing
• Fast turnaround to guide timely antiviral treatment (typically 24–48 hours)
• Supports infection-control and reduces household transmission risk
• Secure reporting compatible with UAE healthcare provider needs

• Nasal and/or throat swab collection performed by a trained technician at home
• No fasting required; avoid strong nasal sprays immediately before sampling
• Inform the team about recent antiviral medications or recent influenza vaccination
• Provide Emirates ID and full Dubai address for scheduling and documentation